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SHORT REPORT
Routine testing for PALB2 mutations in familial
pancreatic cancer families and breast cancer families
with pancreatic cancer is not indicated
Femme Harinck*,1, Irma Kluijt2, Saskia E van Mil3, Quinten Waisfisz3, Theo AM van Os4, Cora M Aalfs4,
Anja Wagner5, Maran Olderode-Berends6, Rolf H Sijmons6, Ernst J Kuipers1,7, Jan-Werner Poley1,
Paul Fockens8 and Marco J Bruno1
PALB2-mutation carriers not only have an increased risk for breast cancer (BC) but also for pancreatic cancer (PC). Thus far,
PALB2 mutations have been mainly found in PC patients from families affected by both PC and BC. As it is well known that the
prevalence of gene mutations varies between different populations, we studied the prevalence of PALB2 mutations in a Dutch
cohort of non-BRCA1/2 familial PC (FPC) families and in non-BRCA1/2 familial BC (FBC) families with at least one PC case.
Mutation analysis included direct sequencing and multiplex ligation-dependent probe amplification (MLPA) and was performed
in a total of 64 patients from 56 distinct families (28 FPC families, 28 FBC families). In total, 31 patients (48%) originated
from FPC families; 24 were FPC patients (77%), 6 had a personal history of BC (19%) and 1 was a suspected carrier (3.2%).
The remaining 33 patients (52%) were all female BC patients of whom 31 (94%) had a family history of PC and 2 (6.1%) had
a personal history of PC. In none of these 64 patients a PALB2 mutation was found. Therefore, PALB2 does not have a major
causal role in familial clustering of PC and BC in non-BRCA1/2 families in the Dutch population.
European Journal of Human Genetics (2012) 20, 577–579; doi:10.1038/ejhg.2011.226; published online 14 December 2011
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INTRODUCTION
Recently, it has become clear that the Fanconi gene FANCN/PALB2
(partner and localizer of BRCA2) should not only be considered as a
susceptibility gene for breast cancer (BC)1 but also as a susceptibility
gene for pancreatic cancer (PC).2 Mutations in this gene may be
associated with familial clustering of PC and BC.1–10
Previous studies have shown that PALB2-mutation-positive familial
BC (FBC) patients were significantly more likely to have a relative
with PC,5 and that nearly all PALB2-mutation positive familial PC
(FPC) families were affected by at least one BC case.4
Given these findings and the fact that the prevalence of gene
mutations varies between different populations, we aimed to
determine the prevalence of PALB2 mutations in Dutch cohorts of
non-BRCA1/2 FPC patients and of non-BRCA1/2 FBC patients with a
personal or family history of PC.
MATERIALS AND METHODS
The prevalence of germline mutations in PALB2 was investigated in Dutch non-
BRCA1/2 FPC patients and non-BRCA1/2 FBC patients with a personal or
family history of PC.
FPC families were defined as families with PC in either Z2 first-degree
relatives (FDRs), Z3 relatives (FDR and second-degree relative (SDR)) or 2
SDRs of whom one was o50 years at diagnosis and did not meet diagnostic
criteria of specific other cancer syndromes.11 These families were identified in
the registries of the Clinical Genetic Centres of Amsterdam (Academic Medical
Centre-University Medical Centre Amsterdam and Netherlands Cancer Insti-
tute), Rotterdam (Erasmus MC-University Medical Centre Rotterdam), and
Groningen (University Medical Centre Groningen), consisting of a total of
40 FPC families. In 28 of these families, DNA was available for PALB2
mutation analysis. In families in which DNA was available of multiple family
members affected by PC, PALB2 mutation analysis was performed in DNA
of all cases. In families without available DNA from PC patients, mutation
analysis was performed in family members affected by BC. In one family,
mutation analysis was performed in a suspected carrier; this suspicion was
based on the position of this individual in the pedigree; this specific case had
a sibling with PC and a child with PC.
The FBC patients were taken from the registry from the Netherlands Cancer
Institute and consisted of non-BRCA1/2 BC patients that fulfilled the Dutch
clinical criteria for BRCA1 and BRCA2 mutation testing, which include (1) BC
diagnosis at ageo35 years, (2) bilateral BC of which one diagnosis at ageo50
years, (3) at least two FDR with BC at an ageo50 years, (4) at least three FDR
or SDR with BC, and (5) one o50 years at diagnosis. From this registry,
patients with a personal history of both BC and PC, and BC patients with a
FDR or SDR with PC were selected. In families in which DNA was available of
multiple affected family members, PALB2 mutation analysis was performed in
all cases.
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At the time of genetic counselling, patients had given written
informed consent to use their DNA for the search for new cancer-
susceptibility genes.
Sequencing and multiplex ligation-dependent probe amplification
(MLPA)
The presence of germline mutations in PALB2 was evaluated by direct
sequencing of the entire coding region and by sequencing intron–exon
boundaries on genomic DNA isolated from whole blood. Primer pairs that
were used have been previously described.12
The presence of large genomic deletions in PALB2 was analysed by MLPA
using the MLPA P057 kit of MRC-Holland (Amsterdam, The Netherlands) as
previously described.13 As a positive control, genomic DNA from the previously
described PALB2 FA patient EUFA1341 was included in the analysis.12
RESULTS
PALB2 mutation analysis was performed in a total of 64 patients from
56 distinct families (28 FPC families, 28 FBC families; Table 1).
In total, 31 patients (48%) originated from FPC families; 24 were
FPC patients (77%), 6 had a personal history of BC (19%) and 1 was a
suspected carrier (3.2%). The remaining 33 patients (52%) were all
female BC patients of whom 31 (94%) had a family history of PC and
2 (6.1%) had a personal history of PC.
The 28 FPC families had a total of 70 affected patients with PC of
which 57 (81%) were confirmed by medical (n¼11) or pathology
reports (n¼46) (Table 2). The mean age at time of PC diagnosis was
61 years (SD±11.5). In total, 38 of the PC patients (54%) were male.
Ten FPC families (36%) had at least three family members diagnosed
with PC. Fourteen FPC families (50%) were affected by BC. Among
the 33 tested patients from 28 FBC families, the mean age at
BC diagnosis was 42 years (SD±9.5). The total number of PC cases
was 29, of which 24 (83%) were confirmed by medical (n¼13) or
pathology report (n¼11). The mean age at PC diagnosis was 70 years
(SD±10.9) and 41% (n¼12) of all PC cases were male.
In none of these cases was a PALB2 mutation found by direct
sequencing and MLPA.
DISCUSSION
Our data provide further evidence that there is a limited causal role for
PALB2 mutations in both FPC and FBC, as we did not identify any
PALB2 mutations in our Dutch cohort of 28 FPC families and 28 FBC
families affected with at least one case of PC.
Since the recent recognition of PALB2 as BC- and PC-susceptibility
gene,1,2 a number of studies have been carried out to investigate the role
Table 1 Characteristics of tested families (n¼56) and cases (n¼64)
n %
FPC families n¼28
Total number of cases tested 31
Type of case in whom PALB2 mutation analysis was performed
Personal history of FPC 24 77
Personal history of BC 6 19
Suspected carrier 1 3.2
BC–PC family n¼28
Total number of cases tested 33
Type of case in whom PALB2 mutation analysis was performed
Personal history of BC with FDR or SDR with PC 31 94
Personal history of both BC and PC 2 6.1
Type of Dutch clinical criteria for BRCA1/2 mutation testing per family
BC diagnosis at age o35 years 6 21
Bilateral BC, one diagnosis at age o50 years 2 7.1
Z2 FDR with BC at age o50 years 12 43
Z3 FDR or SDR with BC, one o50 years at diagnosis 8 29
Table 3 Overview of literature on role of PALB2 mutations in FPC and in BC families affected by PC
Role of PALB2 mutations in FPC
Population (families) PALB2+families
Total FPC FPC with BC
Study Country n n n n (%, 95% CI) PALB2+families with BC
Jones2 USA 96 96 n.s. 3 (3.1, n.s.) 2/3 (75%)
Tischkowitsh4 Canada 101 80 21 1 (1.0, n.s.) 1/1 (100%)
Slater10 Europe 81 67 15 3 (3.7, 0.8–10.4%) 3/3 (100%)
Current study The Netherlands 28 14 14 0 (0, n.a.) n.a.
Role of PALB2 mutations in BC families affected by PC
Population (families) PALB2+families
Total Pers. Hx BC and F/SDR PC Pers. Hx BC and PC
Study Country n n n n (%, 95% CI)
Adank14 The Netherlands 45 45 0 0 (0, n.a.)
Peterlongo8 Italy 62 62 0 3 (4.8, 0.99–13.29%)
Stadler9 USA 77 55 22 0 (0, n.a.)
Hofstatter7 USA 94 91 3 2 (2.1, 0.4–6.5%)
Current study The Netherlands 28 26 2 0/28 (0%)
Abbreviations: n.a., not applicable; n.s., not specified.
Table 2 Detailed description of FPC families (n¼28) and PC-affected
FBC families
FPC families n¼28
Total number of PC cases (n) 70
Confirmed by medical or pathology report (n, %) 57 81
Mean age at PC diagnosis (years, SD) 61 11.5
Mean age at PC diagnosis in tested case n¼24 (years, SD) 60 11.4
Male gender of PC case (n, %) 38 54
Number of families Z3 family members diagnosed with PC (n, %) 10 36
Number of families affected by BC (n, %) 14 50
BC–PC families n¼28 and cases n¼33
Mean age at BC diagnosis in tested case (years, SD) 42 9.5
Total number of PC cases (n) 29
Confirmed by medical or pathology report (n, %) 24 83
Mean age at PC diagnosis (years, SD) 70 11.9
Male gender of PC case (n, %) 12 41
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of PALB2 in different patient populations. Our results are in line with
the results of these previous reports in which no PALB2 mutations,9,14
or low prevalence of PALB2 mutations,2,4,7–8,10 were found. It should be
mentioned that the relatively small sample size could be a possible
explanation for that no mutation carrier was identified in the current
study. Even if a larger sample size might have detected sporadic cases, its
results do show that the role of PALB2 in this particular setting is
insignificant. When combining our data with the previously published
data, PALB2 is involved in only 2.3% (7/306, range 0–3.7%, 95% CI
0.6–40%) of all FPC families and in 1.6% (5/306, range 0–4.8%, 95% CI
0.21–31%) of all FBC families with PC cases (Table 3).
Although PALB2 is involved in the clustering of both PC and BC, it
explains only a small fraction of the clustering, and it is therefore
crucial that future research is directed towards identifying the gene(s)
that are involved in the development of both FPC and FBC. Know-
ledge of additional PC- and BC-susceptibility genes will be helpful in
the counselling of family members from FPC and FBC families, as this
will improve our ability to identify individuals at increased risk of
developing PC and BC. Furthermore, it will have implications on the
effectiveness of screening which will be highest when only directed
towards individuals at risk.
In conclusion, our results provide further evidence for the low
prevalence of PALB2 mutations among non-BRCA1/2 FPC families
and FBC families with PC cases. Therefore, routine analysis of this
gene in these families is not warranted. Future research should be
directed towards specifying subtypes of FPC/FBC families in which
PALB2 analysis is useful towards identifying other gene(s) involved in
the development of PC and BC.
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